地西他滨抑制AML1—ETO+白血病细胞增殖和诱导凋亡的机制研究(5)
[14]Ritchie EK,Feldman EJ,ChristosPJ,et al. Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia[J]. Leuk Lymphoma,2013,54(9):2003-2007.
[15]Daver N,Kantarjian H,Ravandi F,et al. A phase Ⅱ study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome[J]. Leukemia,2016,30(2):268-273.
[16]Braun T,Itzykson R,Renneville A,et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia:A phase 2 trial[J]. Blood,2011, 118(14):3824-3831.
[17]靖彧,朱成英,張琪,等.地西他滨联合改良CAG方案治疗AML1-ETO阳性复发、难治急性髓系白血病的临床研究[J]. 中国实验血液学杂志,2014,22(5):1245-1250.
[18]刘强,费小明.地西他滨联合CAG方案治疗AML1-ETO+AML的临床效果[J].中国实验血液学杂志,2016,24(5):1334-1338.
[19]Man N,Tan Y,Sun XJ,et al. Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1 dependent manner[J]. Blood,2017,129(20): 2782-2792.
[20]Li Y,Gao L,Wang L,et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21)acute myeloid leukemia by activating the PTEN/PI3K signal pathway[J]. Blood,2013,121(3):499-509.
(收稿日期:2018-01-15), 百拇医药(李海英 周斌 张力 高申孟)
[15]Daver N,Kantarjian H,Ravandi F,et al. A phase Ⅱ study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome[J]. Leukemia,2016,30(2):268-273.
[16]Braun T,Itzykson R,Renneville A,et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia:A phase 2 trial[J]. Blood,2011, 118(14):3824-3831.
[17]靖彧,朱成英,張琪,等.地西他滨联合改良CAG方案治疗AML1-ETO阳性复发、难治急性髓系白血病的临床研究[J]. 中国实验血液学杂志,2014,22(5):1245-1250.
[18]刘强,费小明.地西他滨联合CAG方案治疗AML1-ETO+AML的临床效果[J].中国实验血液学杂志,2016,24(5):1334-1338.
[19]Man N,Tan Y,Sun XJ,et al. Caspase-3 controls AML1-ETO-driven leukemogenesis via autophagy modulation in a ULK1 dependent manner[J]. Blood,2017,129(20): 2782-2792.
[20]Li Y,Gao L,Wang L,et al. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21)acute myeloid leukemia by activating the PTEN/PI3K signal pathway[J]. Blood,2013,121(3):499-509.
(收稿日期:2018-01-15), 百拇医药(李海英 周斌 张力 高申孟)